Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst sentiment is moderately bullish: Seven firms collectively rate Parabilis Medicines “Moderate Buy,” with four buys, one strong buy, one hold and one sell. The average 12-month price target is $41.67.
• Shares are near their 52-week high: PBLS opened at $41.73, compared with a 52-week range of $24.51 to $42.49, and its 50-day moving average is $35.93.
• Recent quarterly results missed expectations: The company reported a loss of $2.32 per share versus the consensus loss estimate of $0.16, with quarterly revenue of only $0.15 million. Analysts expect a full-year loss of approximately $2.05 per share.

Parabilis Medicines, Inc. (NASDAQ:PBLS - Get Free Report) has received an average rating of "Moderate Buy" from the seven research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $41.6667.

A number of equities research analysts have issued reports on PBLS shares. Wall Street Zen upgraded shares of Parabilis Medicines to a "hold" rating in a research report on Saturday, June 20th. Evercore assumed coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set an "outperform" rating on the stock. Weiss Ratings started coverage on shares of Parabilis Medicines in a research note on Friday, September 4th. They issued a "sell (d)" rating on the stock. Leerink Partners started coverage on Parabilis Medicines in a report on Monday, July 6th. They set an "outperform" rating and a $40.00 price objective for the company. Finally, Lifesci Capital upgraded Parabilis Medicines to a "strong-buy" rating in a report on Monday, July 6th.

Parabilis Medicines Stock Performance

Shares of PBLS opened at $41.73 on Friday. The firm has a 50-day simple moving average of $35.93. Parabilis Medicines has a fifty-two week low of $24.51 and a fifty-two week high of $42.49.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The company had revenue of $0.15 million for the quarter. On average, sell-side analysts expect that Parabilis Medicines will post -2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Parabilis Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $113,000. Alyeska Investment Group L.P. acquired a new position in Parabilis Medicines in the second quarter worth approximately $274,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Parabilis Medicines during the second quarter valued at approximately $526,000. WINTON GROUP Ltd bought a new position in Parabilis Medicines during the second quarter valued at approximately $955,000. Finally, Squarepoint Ops LLC acquired a new stake in Parabilis Medicines in the second quarter valued at approximately $1,327,000.

About Parabilis Medicines

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.